Tagged with OP

Vaccines MSD’s Cyril Schiever outlines why vaccine hesitancy is such a threat to global health, the misinformation around vaccines being spread online, and how multi-stakeholder collaboration can help counter this emerging problem.   The World Health Organization (WHO) recently identified vaccine hesitancy as one of the top 10 global health threats…

Brazil Rodrigo Araujo of global organizational consulting firm Korn Ferry outlines what he sees as the leadership profile of the future – agile, digital, self-aware, and able to transform both themselves and their organizations.   What are the qualities you look for in a Country Manager? Capable leaders are those who…

USA Eurasia Group’s Aditya Bhattacharji looks at the potentially damaging fallout of the ongoing US-China trade war on the life sciences industry.   Biotech [is the] new frontier for US-China tensions The G20 gathering in Osaka at the end of June was, overall, less tense than other multilateral fora over the…

Egypt Egypt has seen a decade of great transformation, from political instability and uncertainty to its current relative stability. Healthcare reform now stands near the top of the government’s agenda and efforts are being made to roll out universal healthcare and provide greater access to affordable treatments to the entire population. …

Opinion Ulrich Neumann of Certara outlines recent developments in the use of real-world evidence (RWE) and the sizeable impact it stands to make on the global biopharma industry.   While the collection of real-world data is not new, real-world evidence is poised to have a profound impact on the biopharma industry…

Taiwan Dr Jan-Mou Lee, founder of FullHope Biomedical, shares his story of how he came to establish his company after a realization about the loss of impact that occurs when critical research is never transferred outside of the laboratory. Dr Lee goes on to explain his Full Hope’s revolutionary platform that…

USA Chip Davis of the Association for Accessible Medicines argues that learning from the European biosimilars approval experience could speed up patient access to these complex drugs in the USA.   Advancements in biologic research and development have brought forth life-saving treatments for patients with cancer as well as such chronic…

Opinion David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in the cell and gene therapy market for investments and deal activities.   Background Cell and gene therapies hold the promise of bringing significant clinical benefits to patients by directly targeting the underlying cause of disease. With tremendous…

Janssen PharmaBoardroom recently sat down with Janssen EMEA head Kris Sterkens, who outlined the enduring importance of Europe to the global group, even with the emergence of Asian power markets such as China and the continuing significance of the USA. Read the full interview here.   Where Europe really does excel…

USA US industry veteran Sharon Ayd describes her journey to becoming a pharma company board member, the various hurdles still facing female pharma executives, and the responsibility of women at the top to “pay it back” and help the next generation of female leaders.   As I climbed the corporate ladder,…

Top 10 Novartis takes the top spot for the third consecutive year, while Takeda reports the highest growth.   

Europe European MidPharmas – R&D based pharmaceutical companies with annual revenues of between EUR 50 million and 5 billion – are having to be increasingly focused and resilient to succeed and fend off their inherent vulnerabilities according to a new report from specialist pharma and biotech consultancy Novasecta.   Focus 75…